Ezabenlimab (BI-754091) is a humanized monoclonal antibody targeting programmed cell death protein-1 with antitumor activity that blocks the interaction of PD-1 with PD-L1 and PD-L2, inhibits tumor growth in vivo, and can be used to study advanced solid tumors.

IFN-γ:0.9 nM (EC50), PD-1/PD-L1 (cynomolgus Monkeys):5.61 nM (IC90), PD-1/PD-L2 (cynomolgus Monkeys):7.54 nM (IC90), PD-1/PD-L1 (CHO cells):4.14 nM (IC90), PD-1/PD-L2 (CHO cells):3.98 nM (IC90)

Ezabenlimab inhibited the interaction of PD-1 with PD-L1 and PD-L2 in CHO cells with IC90 of 4.14 nM and 3.98 nM, respectively; it also inhibited the interaction of PD-1 with PD-L1 and PD-L2 in cynomolgus Monkeys with IC90 of 5.61 nM and 7.54 nM, respectively.
In addition, Ezabenlimab was able to increase IFN-γ secretion in CD3-positive T cells after primary human antigen stimulation, with an EC50 of 0.9 nM.
In combination with BI 754111, 200 nM Ezabenlimab enhanced IFN-γ secretion. [1]

In the hPD-1 knock-in mouse model, intraperitoneal injection of 0.3-30 mg/kg Ezabenlimab, single or twice a week or every 3 weeks, inhibited tumor progression and demonstrated significant antitumor activity. [1]